Fundraising Fox
Cebiotex
3 known investors
Find your way into Cebiotex
373 people in our graph can introduce you to the Cebiotex team.
Sign up to see every warm intro you have to Cebiotex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cebiotex team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cebiotex is a biotech company developing innovative pharmaceutical products using proprietary nanofiber-based drug delivery technology, with a focus on oncology and surgical applications. The company pursues a partnership and licensing model with pharmaceutical firms to scale and distribute therapies globally.
Founders & leadership
JT
Joan TorrejonCEOJoan Torrejon has held marketing and sales roles at multiple pharmaceutical companies including KabiPharmacia, UCB, Almirall, Calier, and Esteve, with experience in business development and commercial expansion in Latin America and Europe. He is co-founder and leads Cebiotex, a biotech firm developing nanofiber-based drug delivery technologies for oncology and surgical applications.
Investors · 3
Funding
SEC filings, press & company announcements- Undisclosed amountsecond funding roundFeb 2017Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Cebiotex do?
- Cebiotex is a biotech company developing innovative pharmaceutical products using proprietary nanofiber-based drug delivery technology, with a focus on oncology and surgical applications. The company pursues a partnership and licensing model with pharmaceutical firms to scale and distribute therapies globally.
- Who are Cebiotex's investors?
- Cebiotex's investors include Capital Cell, Inveready Technology Investment Group, Ship2B.